QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Donanemab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Donanemab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the regulatory role of regional product information in donanemab pharmacovigilance?

Current regional product information defines the applicable authorised context, while scientific and operational assessments must be mapped to the relevant jurisdiction A single global label always determines indication, monitoring and combination requirements in every jurisdiction Regional differences matter only for marketing and not for case assessment Operational recommendations in a scientific review automatically replace local regulatory requirements

Question 2 of 10 Why should absence of spontaneous reports not be interpreted as proof that an adverse event does not occur?

Events may be difficult to recognise or report, and the product may be used in a specialised population with limited reporting opportunity Spontaneous reports are always complete, so absence proves safety An event cannot occur unless it has already appeared in a safety database Under-reporting is relevant only for non-serious events

Question 3 of 10 Why is the distinction between deposited amyloid beta and a nonspecific immune stimulus important when assessing a suspected adverse reaction?

It helps focus the assessment on the pathway and biological compartment affected rather than assuming generalized immune activation It proves that immune-mediated adverse events cannot occur with donanemab It means that product quality attributes are irrelevant to clinical safety It eliminates the need to consider the patient's underlying Alzheimer's disease

Question 4 of 10 Which set of information is most useful for evaluating a serious or opportunistic infection in a donanemab case?

Infection site, organism, cultures, imaging, antimicrobial treatment, immune status and outcome Only the date of the last infusion and the patient's preferred term Only whether the infection required hospitalisation The product batch without clinical findings or microbiological information

Question 5 of 10 Which approach best reflects the article's treatment of Fc characteristics, glycosylation and other critical quality attributes?

They may influence product behaviour or immunogenicity, so the exact product and presentation should be preserved where available They determine clinical causality independently of the patient's symptoms and chronology They are relevant only during clinical development and not during post-authorisation surveillance They can be ignored whenever the active substance name is known

Question 6 of 10 Which statement best describes the relationship between donanemab's mechanism and amyloid-related imaging abnormalities?

The mechanism creates a biologically plausible safety hypothesis that should guide targeted follow-up, but does not prove causality in an individual case The mechanism establishes that every cerebral imaging abnormality after treatment is caused by donanemab The mechanism is unrelated to imaging findings because monoclonal antibodies act only in the bloodstream The mechanism allows imaging abnormalities to be coded without recording clinical findings or timing

Question 7 of 10 A case report describes a neurological event occurring after donanemab, but gives no indication, treatment intent or disease-status information. What is the main pharmacovigilance concern?

The reviewer may be unable to distinguish disease morbidity or progression from a treatment-related effect The case automatically becomes invalid because treatment intent is never relevant The missing information affects only commercial reporting and not medical assessment The absence of indication proves that the product was used outside its authorised context

Question 8 of 10 Why should delayed, recurrent or multi-system events remain visible during follow-up after an interruption or discontinuation?

Biological effects and clinical manifestations may persist or evolve beyond the next scheduled dose, so stopping follow-up can miss important safety information Only events occurring on the infusion day are relevant to monoclonal antibodies Discontinuation automatically establishes that later events are unrelated Delayed events should be excluded because they cannot contribute to signal detection

Question 9 of 10 Which stratification would be most appropriate when reviewing whether an adverse-event pattern differs across patient groups?

Indication, disease severity, treatment line, monotherapy or combination, duration, age, baseline function, prior therapy and region Only the reporter's country and the product's marketing authorisation date Only the event preferred term and whether the case was expedited Only the patient's sex, regardless of treatment context or disease severity

Question 10 of 10 What is the central governance test for an effective pharmacovigilance system for donanemab?

Whether procedures produce reliable, traceable evidence that cases are recognised, followed up, medically assessed and used in aggregate review Whether the organisation has written procedures, regardless of how they operate in practice Whether every reported event is attributed to donanemab to maximise sensitivity Whether safety review is limited to events already listed in product information

Professional Knowledge Assessment: Donanemab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings